【英文名】renal cell carcinoma 【缩写】【别名】adenocarcinoma of kidney；dear-cell carcinoma of kidney；肾癌；肾实质癌；肾腺癌；透明细胞癌；hypernephroid carcinoma；renal cell carcinoma of kidney；肾上腺样癌 【ICD号】C64 【概述】肾肿瘤(renal tumor)在泌尿系肿瘤中较常见，仅次于膀胱肿瘤。绝大多数原...
【英文名】renalcellcarcinoma 【别名】adenocarcinomaofkidney;dear-cellcarcinomaofkidney;肾 癌;肾实质癌;肾腺癌;透明细胞癌;hypernephroidcarcinoma;renalcell carcinomaofkidney;肾上腺样癌 【ICD号】C64 【病因和发病机制研究的进展】 1.病因研究进展 2.发病机制研究进展肾细胞癌(renalcellcancer,RCC)是泌尿系统肿...
The advent of PD1/PD-L1 inhibitors has significantly transformed the therapeutic landscape for clear cell renal cell carcinoma (ccRCC). This review provides an in-depth analysis of the biological functions and regulatory mechanisms of PD1 and PD-L1 in ccRCC, emphasizing their role in tumor immune ...
Four hundred and seventy-five renal cell carcinomas had a diameter >1 cm and 161 autopsies had a status after nephrectomy. The mean tumour diameter was 3.9±4 cm (median 2 cm). The average age of tumour patients at autopsy was 71.9±11 years. The mean age of patients after nephr...
renal cell carcinoma; inflammation; immune cells; anti-inflammatory therapies 1. Introduction Renal cell carcinoma (RCC) accounts for 95% of kidney-related malignancies and is considered a heterogeneous group of diseases that are classified according to their histological characteristics [1,2]. The ...
International Journal of Molecular Sciences Article Role of Nuclear Claudin-4 in Renal Cell Carcinoma Takuya Owari 1,2, Takamitsu Sasaki 1, Kiyomu Fujii 1, Rina Fujiwara-Tani 1, Shingo Kishi 1, Shiori Mori 1, Takuya Mori 1, Kei Goto 1, Isao Kawahara 1, Yasushi Nakai 2, Makito Miyake 2...
Regarding DM, adenosquamous carcinoma had an odds ratio of 363, BSCC an odds ratio of 680, and spindle cell carcinoma (SpCC) an odds ratio of 391. A poor OS outcome was significantly associated with SpCC, displaying a hazard ratio of 161.The heterogeneity of DM rates was evident amongst ...
Regarding DM, adenosquamous carcinoma had an odds ratio of 363, BSCC an odds ratio of 680, and spindle cell carcinoma (SpCC) an odds ratio of 391. A poor OS outcome was significantly associated with SpCC, displaying a hazard ratio of 161.The heterogeneity of DM rates was evident amongst ...
Efforts to prevent and/or better manage these events may reduce health care costs.May HagiwaraRohit BorkerGerry OsterClinical TherapeuticsEconomic Burden of Adverse Events in Patients With Metastatic Renal Cell Carcinoma[J] . May Hagiwara,Rohit Borker,Gerry Oster.Clinical Therapeutics . 2013 (12)...
MN, USA; 2Pfizer Inc, New York, NY, USA; 3United BioSource Corporation, London, UK Introduction: Survival and best supportive care (BSC) costs for patients with metastatic renal cell carcinoma (mRCC), after stopping therapy, are poorly characterized yet an important aspect of patient care. ...